Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors

Morgensztern, 2012, Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer, J. Thorac. Oncol., 7, 1485, 10.1097/JTO.0b013e318267223a Paz-Ares, 2018, Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer, N. Engl. J. Med., 379, 2040, 10.1056/NEJMoa1810865 Gadgeel, 2020, Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer, J. Clin. Oncol., 38, 1505, 10.1200/JCO.19.03136 West, 2019, Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol., 20, 924, 10.1016/S1470-2045(19)30167-6 Socinski, 2018, Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC, N. Engl. J. Med., 378, 2288, 10.1056/NEJMoa1716948 Reck, 2021, Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion Score >/= 50, J. Clin. Oncol., 39, 2339, 10.1200/JCO.21.00174 Paz-Ares, 2022, First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 Part 1 Trial, J. Thorac. Oncol., 17, 289, 10.1016/j.jtho.2021.09.010 Garon, 2014, Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial, Lancet, 384, 665, 10.1016/S0140-6736(14)60845-X Yoneshima, 2021, Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC, J. Thorac. Oncol., 16, 1523, 10.1016/j.jtho.2021.03.027 Sculier, 2000, A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer, Lung Cancer, 29, 67, 10.1016/S0169-5002(00)00099-4 Fossella, 2000, Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group, J. Clin. Oncol., 18, 2354, 10.1200/JCO.2000.18.12.2354 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Khan, 2018, Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa, Nat. Rev. Clin. Oncol., 15, 310, 10.1038/nrclinonc.2018.9 Huinen, 2021, Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes, Nat. Rev. Clin. Oncol., 18, 527, 10.1038/s41571-021-00496-y Passaro, 2022, Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies, J. Clin. Oncol., 40, 598, 10.1200/JCO.21.01845 Herbst, 2021, Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC, J. Thorac. Oncol., 16, 289, 10.1016/j.jtho.2020.10.004 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Reckamp, 2022, Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A, J. Clin. Oncol., 40, 2295, 10.1200/JCO.22.00912 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627 Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7 Rittmeyer, 2017, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 389, 255, 10.1016/S0140-6736(16)32517-X Zawacki, 2009, Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy, J. Vasc. Interv. Radiol., 20, 624, 10.1016/j.jvir.2009.01.022 Erinjeri, 2011, Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement, Cancer, 117, 1296, 10.1002/cncr.25573